Pay in 4 interest-free payments of $7.40 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Third, the compound has shown a favorable safety profile in preclinical studies
Gallbladder disease, including gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis), has been reported with GLP-1 receptor agonists as a class
Human obesity studies were also conducted during pharmaceutical development, but the largest reported placebo-controlled study did not demonstrate a statistically significant weight-loss benefit, and development for obesity was discontinued
Medical Review Status Last reviewed: June 2026 | Next review: December 2026 Written by Dr
US$ 21.52
US$ 25.45
US$ 23.26
US$ 28.79
US$ 29.35
US$ 21.80
US$ 21.66
US$ 25.95
US$ 24.52
US$ 23.63
